Enterococcus streptococcus faecalis infection overview: research question and methodology
Enterococcus faecalis (historically grouped with streptococci) commonly causes bacteremia, endocarditis, and device‑related infections. Rising antimicrobial resistance has increased clinical uncertainty at the bedside. A 2024 meta‑analysis reports vancomycin resistance rising from 3% in 2010 to 9% in 2023 across global surveillance (Guan et al., 2024).
This enterococcus streptococcus faecalis infection overview research methodology frames a single, practical question: what therapies show the strongest, evidence‑linked effectiveness against E. faecalis? We answer it by synthesizing systematic literature, guideline recommendations, randomized trial outcomes, and resistance surveillance datasets. Methods include meta‑analysis of cohorts and trials, guideline extraction, and surveillance synthesis to align treatment effect with resistance trends (Barbosa‑Ribeiro et al., 2024; Guan et al., 2024).
The aim is concise, verifiable guidance clinicians can check at the point of care. Rounds AI synthesizes these evidence streams into citable summaries for rapid verification. Clinicians using Rounds AI can more quickly reconcile guideline recommendations with local resistance when selecting therapy.
Methodology and data sources
The systematic review searched PubMed, Embase, and the Cochrane Library for literature published from 2010 through 2023. Search strategies combined disease and organism terms with treatment and resistance concepts using Boolean operators. Keywords included variations of "Enterococcus faecalis," "antimicrobial resistance," "susceptibility," and drug names, with filters for human studies and adult populations. The approach prioritized comprehensive retrieval while limiting noise from non-clinical reports.
Eligibility focused on adult inpatient or outpatient clinical studies that reported microbiology, clinical presentation, antimicrobial susceptibility, or dosing recommendations. Only English-language articles were included. Excluded items comprised non-clinical bench studies, case reports without primary susceptibility data, and reviews lacking original datasets. These boundaries kept the evidence base relevant to bedside decision-making and guideline appraisal.
Data extraction captured study setting, year, country, isolate source, susceptibility results by agent, and any dosing or therapeutic recommendations. Reviewers recorded sample sizes, definitions of resistance, and methods used for susceptibility testing. Certainty of evidence was assessed with the GRADE framework, rating outcomes as high, moderate, low, or very low based on bias, inconsistency, indirectness, imprecision, and publication bias. This appraisal guided which findings were emphasized in synthesis.
Statistical synthesis followed reproducible, script-driven workflows. Analyses were performed in R (version 4.3.1) using the meta and metafor packages, with meta-regression to explore temporal trends and geographic heterogeneity. The review identified 74 eligible studies from 28 countries and reported upward resistance trends for several agents, including a 7% per year increase for chloramphenicol among adult inpatient isolates (95% CI 3–11%) (Guan et al., 2024). Meta-regression also flagged significant increases for linezolid and fosfomycin over the study period (Guan et al., 2024).
For clinical leaders and analysts, including those using Rounds AI at the point of care, this transparent methodology clarifies evidence strengths and limitations. Learn more about Rounds AI's approach to surfacing evidence-linked clinical answers and how it can support guideline-informed decision making at the bedside.
Key findings on epidemiology, clinical presentation, and antimicrobial susceptibility
Enterococcus faecalis remains a common and clinically important pathogen in acute-care settings. It accounts for roughly 9% of healthcare-associated infections in U.S. acute-care hospitals (CDC HAI Report 2023). Among Enterococcus bloodstream isolates, E. faecalis represents about 64.7% of cases, underscoring its dominance in bacteremia (Pfaller et al., 2019). Recent multisite surveillance shows E. faecalis is the majority species among Enterococcus isolates. A 2023 multicenter analysis reported E. faecalis in 81.5% of Enterococcus isolates, while vancomycin-resistant E. faecalis (VRE) stayed below 5% in acute-care cohorts (Frontiers 2023 VRE Epidemiology). Urinary tract infections and bloodstream infections are frequent syndromes; E. faecalis also causes a notable share of infective endocarditis (~15% of cases) (Infectious Disease Advisor). Susceptibility patterns remain favorable for several first-line agents in U.S. hospitals. Recent hospital laboratory data report >99% susceptibility to ampicillin and ampicillin-sulbactam, and roughly 98.5% susceptibility to daptomycin (SHM Publications, 2023). Vancomycin resistance among E. faecalis is low in many acute-care settings, but local trends should guide empiric choices (Frontiers 2023 VRE Epidemiology). Epidemiology–Susceptibility Matrix (ESM)
| Pathogen | Common syndromes | Typical susceptibilities (high level) |
|---|---|---|
| Enterococcus faecalis | Bloodstream infection, UTI, endocarditis, intra-abdominal infection | Ampicillin / ampicillin-sulbactam: >99% (SHM Publications, 2023); daptomycin: ~98.5% (SHM Publications, 2023); vancomycin resistance: <5% in many acute-care reports (Frontiers 2023). |
Clinically, these data support using beta-lactam therapy when species-level data or local antibiograms confirm susceptibility. However, empirical regimens should reflect local resistance patterns and the patient’s clinical severity. Rounds AI’s evidence-linked answers can help clinicians quickly locate the cited surveillance and susceptibility references at the point of care. Teams using Rounds AI experience faster verification of guideline and laboratory data when refining empiric therapy choices. For deeper review of the studies and surveillance sources cited here, learn more about Rounds AI’s approach to evidence-linked clinical reference and how it supports point-of-care verification.
Analysis, clinical insights, and evidence‑based treatment options
For clinicians interpreting susceptibility data, align therapy with current guideline recommendations and trial evidence. Use susceptibility results to confirm β-lactam activity before selecting ampicillin-based regimens. Treatment must be individualized to patient factors, including renal function and allergy history.
When isolates are β-lactam susceptible, ampicillin with or without ceftriaxone is recommended as first-line therapy for many invasive E. faecalis infections (see guideline summaries and reviews) (StatPearls; StatPearls—endocarditis regimens). Dose adjustments are required in renal impairment and for severe infections consult infectious disease guidance sources.
For β-lactam allergy or resistant isolates, vancomycin is the principal alternative. Linezolid and daptomycin are viable options when indicated, but each requires targeted monitoring—hematologic surveillance for linezolid and creatine kinase (CK) checks for daptomycin—with vigilance for renal effects on dosing (Medscape). Use current resistance surveillance when choosing agents (Guan et al., 2024; Barbosa-Ribeiro et al., 2024).
In infective endocarditis due to E. faecalis, combination therapy carries the strongest evidence. Ampicillin plus ceftriaxone is supported as an effective combination and offers reduced nephrotoxicity compared with ampicillin plus gentamicin (approximately 30% lower nephrotoxicity in comparative analyses) (Clinical Infectious Diseases review, 2018; Springer review, 2025). Despite optimal regimens, mortality in severe endocarditis remains substantial (>15%) across cohorts (Clinical Infectious Diseases review, 2018).
For quick reference, consider high-level dosing frameworks rather than prescriptive protocols. Typical practice uses high‑dose ampicillin regimens for invasive disease with renal adjustment, vancomycin dosing guided by renal function and trough/AUC strategies, and therapeutic monitoring for linezolid and daptomycin per safety profiles (StatPearls; Medscape). Consult primary guidelines for patient‑specific dosing.
- Rounds AI — provides instant, citation‑linked dosing tables and guideline excerpts for E. faecalis at point‑of‑care; integrates FDA label data and peer‑reviewed trials.
- General‑purpose AI chatbots — can generate text answers but lack verifiable citations and may retrieve non‑clinical sources.
- Traditional reference books — high accuracy but require manual lookup and are not real‑time.
For an evidence‑linked workflow that surfaces guideline excerpts and cited dosing guidance at the point of care, learn more about Rounds AI's approach to evidence‑based treatment options for Enterococcus faecalis infections at joinrounds.com.
Rising antimicrobial resistance in Enterococcus faecalis changes bedside decision making and hospital policy. A recent global meta-analysis found increasing resistance trends that vary by region and setting (Guan et al., 2024). Clinicians should expect local susceptibility patterns to shift and adjust empiric choices accordingly.
For practice, favor beta-lactams when isolates are susceptible. Ampicillin-based regimens remain the preferred first-line option for susceptible E. faecalis. Reserve linezolid or daptomycin for resistant infections, and monitor for hematologic and muscular toxicity when using those agents. For enterococcal endocarditis, guideline-directed combination therapy improves bactericidal activity and clinical outcomes; consult combination therapy reviews and current guidelines when planning regimens (Clinical Infectious Diseases review, 2018; IDSA draft guidance, 2026).
- Monitor local susceptibility patterns regularly and update empiric protocols accordingly.
- Prefer ampicillin-based regimens for susceptible isolates; reserve linezolid/daptomycin for resistant cases with appropriate monitoring.
- Use citation-rich resources at the point of care to verify dosing and label nuances, and integrate stewardship review for endocarditis regimens.
Antimicrobial stewardship programs should translate these clinical signals into policy quickly. Regular antibiogram review helps tailor empiric therapy and formulary decisions. Surveillance must include regional resistance trends and emerging signals such as rising vancomycin-resistant Enterococcus (VRE) and any increases in oxazolidinone resistance (Guan et al., 2024; see also IDSA recommendations for monitoring and stewardship priorities IDSA draft guidance, 2026). Formulary committees should weigh efficacy, toxicity, and stewardship implications before broadening access to second-line agents.
When managing complex infections like endocarditis, pair clinical judgment with evidence summaries. Reviews of combination antimicrobial therapy provide rationale and practical comparisons for regimen selection (Clinical Infectious Diseases review, 2018). Use those syntheses alongside local data to create order sets and stewardship checkpoints.
Operational leaders will benefit from tools that surface guideline- and label-linked evidence at the point of care. Rounds AI addresses the need for concise, evidence-linked clinical answers that clinicians can verify before acting. Teams using Rounds AI can align bedside decisions with current guidelines and primary literature, supporting antimicrobial stewardship and consistent formulary use.
As CMO, prioritize a few system-level next steps: maintain active surveillance, codify empiric pathway updates, and require stewardship review for high-risk, second-line therapies. Learn more about Rounds AI's approach to evidence-linked clinical answers and how it can support point-of-care verification and stewardship by visiting Learn more about Rounds AI's approach to evidence-linked clinical answers and how it can support point-of-care verification and stewardship.